证券代码：600332 证券简称：白云山 公告编号：2025－060 广州白云山医药集团股份有限公司 关于 2025 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 截至 2025 年 6 月 30 日止，本公司募集资金使用情况如下： | 项目 | | | | | 募集资金发生额 （万元） | | --- | --- | --- | --- | --- | --- | | 募集资金净额 | | | | | 786,344.65 | | 减：募投项目累计支出(含置换前期自有资金投入) | | | | | 766,170.29 | | 其中：2024 12 | | 年 | 月 | 31 日前累计支出 | 764,789.53 | | 2025 年 月累计支出 | 1-6 | | | | 1,380.76 | | 减：2024 | | | | 年项目节余资金永久补充流动资金 | 42,655.86 | | 减：银行手续费支出 | | | | | 33.95 | | 减：以闲置募集资金购买 ...

广州白云山医药集团股份有限公司（"本公司"或"公司"）第九届 董事会第二十八次会议于2025年8月15日以现场结合通讯形式召开，审议 通过了《关于修订<广州白云山医药集团股份有限公司章程>相关条款并取 消监事会的议案》《关于修订<广州白云山医药集团股份有限公司股东大 会议事规则>相关条款的议案》以及《关于修订<广州白云山医药集团股份 有限公司董事会议事规则>相关条款的议案》。 证券代码：600332 证券简称：白云山 公告编号：2025－059 广州白云山医药集团股份有限公司 关于修订《公司章程》《股东大会议事规则》及《董事 会议事规则》相关条款并取消监事会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 一、关于修订《广州白云山医药集团股份有限公司章程》及附件议 事规则的情况 根据2024年7月1日生效实施的《中华人民共和国公司法》（"《公司 法》"）、中国证券监督管理委员会发布的《关于新<公司法>配套制度规 则实施相关过渡期安排》以及《上市公司章程指引》（2025年修订）（"《章 程指引》"）等相关法律、行政法规和规 ...

广州白云山医药集团股份有限公司 第九届监事会第十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（"本公司"）第九届监事会第十四 次会议（"会议"）通知于 2025 年 8 月 4 日以书面及电邮方式发出，于 2025 年 8 月 15 日在中国广东省广州市荔湾区沙面北街 45 号本公司会议室召开。 本次会议应出席监事 3 人，实际出席监事 3 人，其中，监事简惠东先生以 通讯方式出席会议。监事会主席刘漤女士主持了会议，会议的召集、召开 符合《公司法》及《公司章程》的规定。 经与会监事审议、表决，会议通过了如下议案： 一、本公司 2025 年半年度报告及其摘要 证券代码：600332 证券简称：白云山 公告编号：2025-057 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票，审议通过本议案。 三、本公司 2025 年半年度募集资金存放与实际使用情况的专项报告 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票，审议通过本议案。 特此公告。 广州白云山医药集团股份 ...

证券代码：600332 证券简称：白云山 公告编号：2025－056 广州白云山医药集团股份有限公司 第九届董事会第二十八次会议决议公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内 容的真实性、准确性和完整性承担法律责任。 二、本公司 2025 年半年度财务报告 表决结果：同意票 9 票、反对票 0 票、弃权票 0 票，审议通过本议案。 本议案已经本公司董事会审核委员会 2025 年第 3 次会议审议通过。 广州白云山医药集团股份有限公司（"本公司"）第九届董事会第二十八 次会议（"会议"）通知于 2025 年 8 月 4 日以书面及电邮方式发出，于 2025 年 8 月 15 日上午在中国广东省广州市荔湾区沙面北街 45 号本公司会议室召开。 本次会议应出席会议董事 9 人，实际出席会议董事 9 人，其中，独立非执行董 事陈亚进先生、黄龙德先生和孙宝清女士以通讯方式出席会议。董事长李小军 先生主持了会议，本公司监事、中高级管理人员及律师列席了会议。会议的召 集、召开符合《公司法》及《公司章程》的规定。 经与会董事审议、表决，会议通过了如下议案： 一、本公司 20 ...

证券代码：600332 证券简称：白云山 公告编号：2025－058 广州白云山医药集团股份有限公司 2025 年中期利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●每股分配比例：每股派发现金红利人民币 0.40 元（含税）。 ●本次利润分配以实施权益分派股权登记日的已发行股份总数为 基数，具体日期将在权益分派实施公告中明确。 ●在实施权益分派的股权登记日前公司已发行股份总数发生变动 的，拟维持分配总额不变，相应调整每股分配比例，并将另行公告具 体调整情况。 一、利润分配方案 截至 2025 年 6 月 30 日，广州白云山医药集团股份有限公司（以 下简称"本公司"或"公司"）母公司报表中期末未分配利润为人民 币 7,568,559,146.29 元。经第九届董事会第二十八次会议决议，公司 将以实施权益分派股权登记日的已发行股份总数为基数分配利润。本 次中期利润分配方案如下： 1、本公司拟向全体股东每股派发现金红利人民币 0.40 元（含税）。 截至 2025 年 6 月 30 日，公司总股 ...

[Definitions](index=4&type=section&id=Section%201%20Definitions) This chapter defines and explains professional terms, company entity abbreviations, and industry-specific vocabulary used in the report - Key professional terms, company entity abbreviations, and industry-specific vocabulary such as GMP, GAP, and GSP are defined and explained[10](index=10&type=chunk)[11](index=11&type=chunk)[12](index=12&type=chunk) [Company Profile and Key Financial Indicators](index=8&type=section&id=Section%202%20Company%20Profile%20and%20Key%20Financial%20Indicators) This chapter presents the company's basic information, listing details, and key financial indicators for H1 2025, highlighting revenue growth, profit decline, and a significant drop in operating cash flow [Company Basic Information](index=8&type=section&id=I.%20Company%20Basic%20Information) This section provides an overview of the company's legal name, contact details, registered addresses, and dual listing information on the Shanghai and Hong Kong stock exchanges - The company is an A+H share dual-listed company, with A-shares listed as **'Baiyunshan' (code 600332)** and H-shares as **'Baiyunshan' (code 0874)**[15](index=15&type=chunk) [Key Accounting Data and Financial Indicators](index=8&type=section&id=II.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) The company reported **RMB 41.835 billion** in operating revenue, a **1.93% increase**, but net profit attributable to the parent declined by **1.31%** to **RMB 2.516 billion**, with operating cash flow significantly decreasing by **66.79%** Key Accounting Data | Key Accounting Data | Current Period (RMB Yuan) | Prior Period (RMB Yuan) | YoY Change (%) | | :--- | :--- | :--- | :--- | | **Operating Revenue** | 41,834,546,114 | 41,042,815,088 | 1.93 | | **Total Profit** | 3,090,416,329 | 3,229,403,377 | (4.30) | | **Net Profit Attributable to Parent Company Shareholders** | 2,516,140,987 | 2,549,565,302 | (1.31) | | **Net Profit Attributable to Parent Company Shareholders (Excluding Non-recurring Items)** | 2,205,589,254 | 2,340,832,630 | (5.78) | | **Net Cash Flow from Operating Activities** | (3,397,136,268) | (2,036,740,495) | (66.79) | | **Basic Earnings Per Share (RMB/share)** | 1.548 | 1.568 | (1.31) | - Net cash flow from operating activities significantly decreased by **66.79%** year-on-year, primarily due to lower receivables collection and increased payments for purchases by the company's subsidiaries during the reporting period[18](index=18&type=chunk) [Non-recurring Gains and Losses Items and Amounts](index=9&type=section&id=IV.%20Non-recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) The company's total non-recurring gains and losses reached **RMB 311 million**, mainly from fair value changes of financial assets/liabilities and government grants Non-recurring Gains and Losses Items | Non-recurring Gains and Losses Item | Amount (RMB Yuan) | | :--- | :--- | | Gains and Losses from Financial Assets and Liabilities Held by Non-financial Enterprises | 240,596,003 | | Government Grants Recognized in Current Profit or Loss | 130,454,564 | | **Total** | **310,551,733** | [Management Discussion and Analysis](index=12&type=section&id=Section%203%20Management%20Discussion%20and%20Analysis) This chapter analyzes the company's operating environment, business segments, core competencies, and financial status, noting slight revenue growth but profit decline, with the Great Health segment performing well while Great Pharmaceutical declined, and the company continues strategic initiatives [Industry and Main Business Overview](index=12&type=section&id=I.%20Overview%20of%20the%20Group%27s%20Industry%20and%20Main%20Business%20During%20the%20Reporting%20Period) The company operates across the pharmaceutical and health industry, segmented into Great Pharmaceutical, Great Health, Great Commercial, and Great Medical, navigating industry slowdowns while leveraging its brand and full-chain presence - The company's business is primarily divided into four segments - **Great Pharmaceutical Segment**: Engages in R&D, manufacturing, and sales of traditional Chinese and Western medicines, raw materials, owning **13** Chinese time-honored pharmaceutical enterprises - **Great Health Segment**: Key products include Wanglaoji herbal tea and Ciningji series, with Wanglaoji herbal tea holding a significant market share in China's herbal tea industry - **Great Commercial Segment**: Engages in wholesale, retail, and import/export of pharmaceutical products and medical devices, with Guangzhou Pharmaceutical as a leading enterprise in South China - **Great Medical Segment**: In the layout and investment expansion phase, focusing on medical services, traditional Chinese medicine wellness, and modern elderly care[24](index=24&type=chunk)[26](index=26&type=chunk)[27](index=27&type=chunk) - In the first half of 2025, operating revenue for national pharmaceutical manufacturing enterprises above designated size decreased by **1.2%** year-on-year, and total profit decreased by **2.8%**, indicating industry-wide pressure from slowing growth and declining profits[29](index=29&type=chunk) [Discussion and Analysis of Operations](index=14&type=section&id=II.%20Discussion%20and%20Analysis%20of%20Operations) In H1 2025, the company's revenue grew by **1.93%** to **RMB 41.835 billion**, but net profit declined by **1.31%** to **RMB 2.516 billion** due to market and policy factors, while strategic initiatives like internationalization and capital operations progressed - The year-on-year decline in the company's profit was primarily due to the continuous impact of insufficient demand, intensified industry competition, and industry policies, leading to a decrease in the operating performance of some businesses[34](index=34&type=chunk) - Key work progress during the reporting period includes - **Internationalization**: Xiaochaihu Granules obtained Macau registration, Wanglaoji launched international dual-label cans, expanding into markets like Saudi Arabia and Malaysia - **Scientific Research**: Obtained **15** drug registration approvals, added **1** national-level platform - **Capital Operations**: Successfully acquired Caishantang, increasing the number of time-honored brands to **13**; Guangzhou Pharmaceutical successfully listed on the New Third Board; completed 2024 annual profit distribution, with cash dividends accounting for **45.87%** of net profit[38](index=38&type=chunk)[39](index=39&type=chunk)[40](index=40&type=chunk) [Core Competitiveness Analysis](index=16&type=section&id=III.%20Core%20Competitiveness%20Analysis%20During%20the%20Reporting%20Period) The company's core competitiveness stems from its extensive product and brand portfolio, rich TCM heritage, comprehensive industrial chain, national distribution network, robust R&D system, and skilled talent pool, which remained stable - The company owns **10** China Well-known Trademarks, and **13** of its member enterprises are certified as Chinese Time-Honored Brands, with **11** of them being century-old enterprises[42](index=42&type=chunk)[43](index=43&type=chunk) - The company has established a multi-level innovation platform system, possessing **6** national-level R&D institutions and **2** postdoctoral workstations, with over **160** ongoing R&D projects covering traditional Chinese medicine, chemical drugs, and biological drugs[46](index=46&type=chunk) [Analysis of Key Operating Performance](index=18&type=section&id=IV.%20Key%20Operating%20Performance%20During%20the%20Reporting%20Period) This section analyzes operating performance across financial items, segments, and regions, noting the Great Health segment's strong growth and improved gross margin, the Great Pharmaceutical segment's decline, and overall stable financial ratios [Other Disclosures](index=28&type=section&id=V.%20Other%20Disclosures) The company faces significant risks from industry policies, R&D uncertainties, product quality control, and market fluctuations, which it plans to mitigate through innovation and digital transformation - Potential risks faced by the company include - **Policy Risks**: Transformation and upgrading pressures from healthcare reform measures such as consistency evaluation, volume-based procurement, and medical insurance payment method reforms - **R&D Risks**: Long development cycles and high investment for innovative drugs, with risks of progress or clinical results falling short of expectations - **Other Risks**: Product quality control risks, market risks, etc[75](index=75&type=chunk) [Corporate Governance, Environment, and Society](index=30&type=section&id=Section%204%20Corporate%20Governance%2C%20Environment%2C%20and%20Society) This chapter details the company's corporate governance, environmental, and social responsibility practices, including board changes, a proposed interim dividend, compliance with listing rules, environmental disclosures, and ongoing rural revitalization initiatives [Changes in Directors, Supervisors, and Senior Management](index=30&type=section&id=I.%20Changes%20in%20the%20Company%27s%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management%20and%20Their%20Information) During the reporting period, the company saw changes in its board and senior management, with Mr. Li Xiaojun elected as Chairman and other key personnel changes due to work transfers or retirement - Mr. Li Xiaojun was elected as the company's Chairman, while Mr. Yang Jun (former Vice Chairman), Mr. Wu Changhai (former Executive Director), and Ms. Liu Juyan (former Executive Director) resigned[79](index=79&type=chunk)[81](index=81&type=chunk) [Profit Distribution Plan](index=30&type=section&id=II.%20Profit%20Distribution%20or%20Capital%20Reserve%20Conversion%20Plan) The board approved the 2025 interim profit distribution plan, proposing a cash dividend of **RMB 4.00 (tax inclusive)** per 10 shares, totaling approximately **RMB 650 million**, with no bonus shares or capital reserve conversions Profit Distribution Plan | Distribution/Conversion Item | Plan | | :--- | :--- | | Dividend per 10 Shares (RMB Yuan, tax inclusive) | 4.00 | | Total Cash Dividend (RMB Yuan, tax inclusive) | 650,316,379.60 | | Bonus Shares per 10 Shares (shares) | / | | Conversion Shares per 10 Shares (shares) | / | [Corporate Governance Status](index=31&type=section&id=V.%20Corporate%20Governance%20Status) The company maintained strong corporate governance, complying with listing rules, disclosing key reports, establishing a market value management system, and strengthening internal control and audit functions - Key corporate governance initiatives include - Disclosure of the 2024 Internal Control Evaluation Report and Sustainable Development Report - Formulation and implementation of the 'Market Value Management System' - Holding **2** shareholder meetings, **8** board meetings, and **3** supervisory board meetings in the first half of 2025 - Establishment of an audit center to coordinate enterprise audit resources and strengthen supervision[85](index=85&type=chunk)[86](index=86&type=chunk)[87](index=87&type=chunk)[88](index=88&type=chunk) [Rural Revitalization Initiatives](index=34&type=section&id=VIII.%20Specific%20Progress%20in%20Consolidating%20Poverty%20Alleviation%20Achievements%2C%20Rural%20Revitalization%2C%20and%20Other%20Initiatives) The company actively promotes rural revitalization through various initiatives, including medical equipment donations, establishing medicinal material planting bases, investing in agricultural industrial parks, and driving local economic development - The company promotes rural revitalization through industrial assistance, with specific measures including - **Targeted Assistance**: Donating medical equipment worth approximately **RMB 350,000** to Nanxing Town Central Health Center in Leizhou City, Zhanjiang - **Industrial Drive**: Developing medicinal material planting base projects in Zhanjiang, Meizhou, Xinjiang, and other regions; investing in the Guangdong Lychee (Maoming, Shantou) Industrial Park; advancing production base projects in Meizhou, Longyan, Guizhou, and other areas[90](index=90&type=chunk) [Significant Matters](index=35&type=section&id=Section%205%20Significant%20Matters) This chapter details the company's significant commitments, related party transactions, use of raised funds, and other important matters, including ongoing commitments, trademark transfer progress, normal related party transactions, and the successful listing of Guangzhou Pharmaceutical on the New Third Board [Fulfillment of Commitments](index=35&type=section&id=I.%20Fulfillment%20of%20Commitments) The company and its controlling shareholder are fulfilling commitments related to the 2013 asset restructuring and Guangzhou Pharmaceutical's New Third Board listing, with most 'Wanglaoji' trademark transfers completed and performance commitment periods adjusted - Controlling shareholder GPHL's long-term commitments regarding maintaining the listed company's independence, avoiding horizontal competition, and regulating related party transactions are being fulfilled[93](index=93&type=chunk)[94](index=94&type=chunk)[95](index=95&type=chunk) - Regarding the commitment for 'Wanglaoji' trademark injection, asset delivery has been completed, and the performance commitment period was adjusted to 2019, 2021, and 2022; as of the end of the reporting period, **398** out of **418** trademarks have completed transfer procedures, with **20** still pending approval[99](index=99&type=chunk) [Significant Related Party Transactions](index=44&type=section&id=X.%20Significant%20Related%20Party%20Transactions) The company conducted normal related party transactions with joint ventures, associates, and common control entities at market prices, and approved a **RMB 150 million** capital increase in Baiyunshan Bio, maintaining its **50.00%** stake - The company engaged in daily related party transactions, including purchase/sale of goods and acceptance/provision of services, with affiliates such as Baiyunshan & Hutchison (joint venture), Yixintang (associate), and Huacheng Pharmaceutical (under common control)[111](index=111&type=chunk)[112](index=112&type=chunk)[113](index=113&type=chunk) - The company increased capital in Baiyunshan Bio by **RMB 150 million**, maintaining its **50.00%** shareholding post-investment; this transaction constitutes a related party transaction and the agreement was signed on June 30, 2025[117](index=117&type=chunk) [Explanation of Progress in Use of Raised Funds](index=49&type=section&id=XII.%20Explanation%20of%20Progress%20in%20Use%20of%20Raised%20Funds) The company's 2016 non-public A-share offering raised **RMB 7.863 billion**, with **97.43%** utilized by June 30, 2025, primarily for 'Great Pharmaceutical' R&D, production bases, 'Wanglaoji' trademarks, and working capital Raised Funds Utilization Progress | Source of Raised Funds | Net Raised Funds (RMB 10,000 Yuan) | Cumulative Investment Amount (RMB 10,000 Yuan) | Cumulative Investment Progress (%) | | :--- | :--- | :--- | :--- | | 2016 Non-public Offering | 786,344.65 | 766,170.29 | 97.43 | [Explanation of Other Significant Matters](index=54&type=section&id=XIII.%20Explanation%20of%20Other%20Significant%20Matters) A key event during the reporting period was the successful listing and public transfer of shares of the controlling subsidiary, Guangzhou Pharmaceutical Co., Ltd., on the New Third Board on May 20, 2025 - The shares of the company's controlling subsidiary, Guangzhou Pharmaceutical Co., Ltd., were successfully listed and publicly traded on the New Third Board on May 20, 2025[125](index=125&type=chunk) [Share Changes and Shareholder Information](index=56&type=section&id=Section%206%20Share%20Changes%20and%20Shareholder%20Information) This chapter details the company's stable share capital structure, shareholder information, including **85,550** shareholders and the controlling shareholder's **45.04%** stake, and employee data, with **27,425** employees and **RMB 2.013 billion** in H1 wages [Shareholder Information](index=56&type=section&id=II.%20Shareholder%20Information) As of June 30, 2025, the company had **85,550** shareholders, with Guangzhou Pharmaceutical Holdings Limited and HKSCC Nominees Limited as the top two, holding **45.04%** and **13.52%** respectively Top Shareholders | Shareholder Name | Shares Held at Period End (shares) | Percentage of Total Share Capital (%) | | :--- | :--- | :--- | | Guangzhou Pharmaceutical Holdings Limited | 732,305,103 | 45.04 | | HKSCC Nominees Limited | 219,783,142 | 13.52 | | Guangzhou Guoshou Urban Development Industrial Investment Enterprise | 67,576,183 | 4.16 | [Employee Information](index=60&type=section&id=IV.%20Employee%20Information%20of%20the%20Group) As of the reporting period end, the Group had **27,425** employees, with total wages of approximately **RMB 2.013 billion** in H1 2025, supported by performance-linked compensation and a comprehensive training system - As of June 30, 2025, the Group had **27,425** employees, with total wages for the first half of the year approximately **RMB 2.013 billion**[138](index=138&type=chunk) [Bond-Related Information](index=62&type=section&id=Section%207%20Bond-Related%20Information) This chapter confirms that the company had no bond-related activities during the reporting period - During the reporting period, the company had no bond-related information[145](index=145&type=chunk) [Financial Report (Unaudited)](index=62&type=section&id=Section%208%20Financial%20Report%20%28Unaudited%29) This chapter presents the company's unaudited 2025 interim consolidated and parent company financial statements, including the balance sheet, income statement, cash flow statement, and detailed notes on accounting policies, key items, and related party transactions [Consolidated Balance Sheet](index=63&type=section&id=Consolidated%20Balance%20Sheet) As of June 30, 2025, total assets increased by **0.90%** to **RMB 82.420 billion**, total liabilities decreased by **2.97%** to **RMB 42.608 billion**, and equity attributable to parent company shareholders grew by **5.17%** to **RMB 37.760 billion** Consolidated Balance Sheet Summary | Item | June 30, 2025 (RMB Yuan) | December 31, 2024 (RMB Yuan) | | :--- | :--- | :--- | | **Total Assets** | 82,419,655,052 | 81,683,611,521 | | **Total Liabilities** | 42,608,420,884 | 43,913,975,774 | | **Equity Attributable to Parent Company Shareholders** | 37,760,172,340 | 35,904,527,869 | [Consolidated Income Statement](index=65&type=section&id=Consolidated%20Income%20Statement) In H1 2025, operating revenue grew by **1.93%** to **RMB 41.835 billion**, but net profit attributable to the parent declined by **1.31%** to **RMB 2.516 billion**, despite decreases in sales and R&D expenses Consolidated Income Statement Summary | Item | Current Period (RMB Yuan) | Prior Period (RMB Yuan) | | :--- | :--- | :--- | | **Operating Revenue** | 41,834,546,113.81 | 41,042,815,087.95 | | **Operating Cost** | 34,171,307,857.09 | 33,244,055,666.85 | | **Selling Expenses** | 3,028,477,834.76 | 3,119,415,170.54 | | **R&D Expenses** | 285,285,159.35 | 391,145,311.41 | | **Net Profit Attributable to Parent Company Shareholders** | 2,516,140,986.67 | 2,549,565,302.08 | [Consolidated Cash Flow Statement](index=66&type=section&id=Consolidated%20Cash%20Flow%20Statement) In H1 2025, net cash flow from operating activities significantly increased its outflow to **RMB -3.397 billion**, investing activities had a net outflow of **RMB 4.723 billion**, while financing activities generated a net inflow of **RMB 1.918 billion**, with period-end cash and equivalents at **RMB 10.107 billion** Consolidated Cash Flow Statement Summary | Item | Current Period (RMB Yuan) | Prior Period (RMB Yuan) | | :--- | :--- | :--- | | **Net Cash Flow from Operating Activities** | (3,397,136,268.03) | (2,036,740,494.59) | | **Net Cash Flow from Investing Activities** | (4,722,774,623.53) | (3,914,678,746.75) | | **Net Cash Flow from Financing Activities** | 1,918,310,698.76 | 595,081,664.61 | | **Cash and Cash Equivalents at Period End** | 10,106,808,592.20 | 14,471,487,165.36 | [Notes to Financial Statements](index=75&type=section&id=Notes%20to%20Financial%20Statements) The notes to the financial statements provide detailed explanations of the company's basic information, accounting policies, major consolidated financial statement items, segment reporting, related party transactions, and contingent liabilities - The notes provide detailed explanations of the revenue, profit, assets, and liabilities for the company's four business segments (Great Pharmaceutical, Great Health, Great Commercial, Other), offering data support for in-depth analysis of each segment's operating performance[528](index=528&type=chunk)[530](index=530&type=chunk) - The notes disclose detailed transaction information with related parties (including the parent company, joint ventures, and associates), covering purchase and sale of goods, provision and acceptance of services, and related party leases[510](index=510&type=chunk)[515](index=515&type=chunk) - Important contingent liabilities are disclosed in the notes, such as the dispute over 'Jinge' profit distribution where no consensus has been reached, and multiple ongoing litigation matters[523](index=523&type=chunk)[533](index=533&type=chunk)

2025年1至6月份，白云山的营业收入构成为：大商业占比69.32%，大健康占比16.79%，大南药占比 12.53%，其他占比1.07%，其他业务占比0.3%。 （文章来源：每日经济新闻） 白云山（SH 600332，收盘价：26.81元）8月15日晚间发布公告称，公司第九届第二十八次董事会会议 于2025年8月15日在中国广东省广州市荔湾区沙面北街45号公司会议室召开。会议审议了《关于提名陈 杰辉先生为公司第九届董事会执行董事候选人并建议其2025年度薪酬的议案》等文件。 ...

本文源自：金融界AI电报 白云山(00874.HK)发布公告，将于2025年9月26日派发中期股息每股0.4399港元。 ...

白云山(00874)发布公告，董事会建议委任陈杰辉为公司第九届董事会执行董事。 ...

智通财经APP讯，白云山(00874)发布公告，将于2025年9月26日派发中期股息每股0.4399港元。 ...